James Lapworth joins NanoSyrinx as Chief Business Officer
Dr James Lapworth has joined the NanoSyrinx management team as Chief Business Officer to support the company in delivering its ambitious plans following the recent announcement of our oversubscribed Seed+ funding round.
James is an experienced business development and technology commercialisation professional with over 10 years’ experience in fundraising, developing, partnering and out-licensing new technologies, particularly in the drug discovery, biotech and med-tech sectors. In his previous role at Warwick Ventures he identified and managed a portfolio of >60 new inventions leading to 6 new spinout companies which raised a total of £10m in seed stage equity financing between 2018-2021. During this time, he also sat on the management committees of the Warwick Integrative Synthetic Biology Centre and the Warwick-Wellcome Translational Partnership.
In earlier roles, he established multiple early-stage discovery partnerships, including supporting Prof Simon Wagner to secure one of Europe’s first GSK Discovery Fast Track Challenge awards, leading to a collaborative partnership with GSK aimed at discovering new medicines for the treatment of non-Hodgkin’s lymphoma.
Joe Healey, CEO, said:
“James has been intimately involved in the establishment of NanoSyrinx over the past 5 years and I am delighted that we have been able to bring him onboard full time to support the company’s growth.”
James holds a First Class dual honours degree in Biology & Chemistry and a PhD in Synthetic Chemistry and Regenerative Medicine from the University of Sheffield. He is a Member of the Royal Society of Chemistry, a Chartered Chemist and a Registered PRINCE2 practitioner.
